



## STUDIES CURRENTLY RECRUITING

### ***MDV3100-14***

A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer **Recruiting**

### ***Dendreon P12-2***

A Randomized, Open-Label, Phase 2 Study of Sipuleucel-T with Concurrent versus sequential Administration of Enzalutamide in Men with Metastatic castrate resistant prostate cancer

### ***ARN-509 - SPARTAN Study***

Phase III study comparing ARN-509 (pill) to placebo for patients with non-metastatic prostate cancer **Recruiting**

### ***Galeterone - TOK ARMOR 2 study***

2 part Phase II study of galeterone -TOK (pill) for patients with metastatic prostate cancer pre and post-chemotherapy **Recruiting**

### ***OGX-011 (Custersin) + Jevtana***

Phase III study of Jevtana +/- Custersin second line chemotherapy for patients with metastatic prostate cancer **Recruiting**

### ***Prolia (denosunab)***

Phase III study to evaluate Prolia for patients with prostate cancer taking hormones **Recruiting**

### ***Prostvac (vaccine)***

Phase III study vaccination study for patients with advanced prostate cancer who have not yet received treatment with chemotherapy and have no symptoms or minimal symptoms **Recruiting**

### ***Provenge PROCEED study (vaccine)***

Registry study to collect long term safety data for patients receiving Provenge vaccine  
**Recruiting**

***Provenge PROCEED sub - study***

Immune response study (additional blood samples collected) for patients participating in PROCEED study **Recruiting**

***PSMA ADC***

Phase II study of PSMA ADC (target chemotherapy) in patients with metastatic prostate cancer who have failed chemotherapy **Recruiting**

***VT-464-CL-001 (testosterone inhibitor)***

Phase I/II study to evaluate the safety of the study drug VT-464 (pill) and how it affects patients with prostate cancer **Recruiting**

***XL184 (Cabozantinib)***

Phase II study comparing XL184 (Cabozantinib) (pill) vs. Prednisone only for patients who have failed Zytiga (abiraterone) or Xtandi (MDV3100) **Recruiting**

***Xtandi (MDV 3100) - STRIVE***

Phase II study comparing Xtandi to standard of care Casodex for patients with Prostate cancer **Recruiting**

***Androgen deprivation vs. Radiotherapy***

Phase III study comparing androgen deprivation prior with pelvic lymph node dissection vs. radiotherapy only **Recruiting**

***Taxotere***

Phase III study to evaluate the addition of Taxotere prior to surgery to improve outcome for patients with newly diagnosed high risk prostate cancer **Recruiting**

***Taxotere +/- GM-CSF***

Phase II study of intermittent Taxotere vs. intermittent Taxotere with GM-CSF **Recruiting**

## STUDIES ACTIVE, CLOSED TO ENROLLMENT

### ***Zytiga – Rising PSA IMAAGEN study***

Phase III study of Zytiga plus prednisone for patients with rising PSA prostate cancer who are receiving hormone therapy **Closed to enrollment – active follow-up**

### ***TAK-700 (Orteronel) Pre-chemotherapy***

Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy **Closed to enrollment – active follow-up**

### ***TAK-700 (Orteronel) Post-chemotherapy***

Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer previously treated with chemotherapy **Closed to enrollment – active follow-up**

### ***TAK-700 (Orteronel)***

Phase II Open-label study of oral TAK-700 plus prednisone, evaluating the effects on the heart for patients with advanced prostate cancer **Closed to enrollment – active follow-up**

### ***TAK-700 (Orteronel)***

Phase II Open-label study of oral TAK-700 plus prednisone, evaluating dosing options for patients with advanced prostate cancer **Closed to enrollment – active follow-up**

### ***Zytiga Cougar 302 study***

Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy **Closed to enrollment – active follow-up**

### ***Zytiga + Provenge***

Open-label Phase II study of Provenge with concurrent or sequential Zytiga. **Closed to enrollment – active follow-up**

## PRIOR STUDIES - CLOSED

### ***Genentec GDC + Zytiga***

Phase II study of GDC + Zytiga, versus Zytiga alone for patients with advanced prostate cancer previously treated with chemotherapy **Closed**

### ***Zytiga Cougar 301 study***

Phase III study of oral Zytiga plus prednisone for patients with advanced prostate cancer who have already received chemotherapy **Closed**

### ***Zytiga EAP study***

EAP oral Zytiga plus prednisone for patients with advanced prostate cancer who have already received chemotherapy **Closed**

### ***MDV3100 EAP study***

EAP oral MDV3100 for patients with advanced prostate cancer who have already received chemotherapy **Closed**

### ***TroVax***

Phase II study to evaluate the addition of TroVax vaccination to standard Taxotere chemotherapy for patients with advanced prostate cancer **Closed**

### ***OGX-011 (Custersin)***

Phase III study of OGX-011 (Custersin) added to Taxotere for second line treatment evaluation of pain palliation **Closed**

### ***Eligard +/- Taxotere - Rising PSA***

A Phase III study Eligard +/- Taxotere for patients with Rising PSA **Closed**